Bhumika J. Patel - Concepedia

Author

Bhumika J. Patel

Cleveland Clinic ORCID

Also Known As

B J Patel, B Patel, B. J. Patel, B. Patel, Bhumika J Patel, Bhumika J. Patel, Bhumika Patel, Patel Bhumika J

148

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Cleveland Clinic University of Rome Tor Vergata Case Western Reserve University Cleveland Clinic Lerner College of Medicine Munich Leukemia Laboratory (Germany)

About

Bhumika J. Patel is an author at Cleveland Clinic specializing in hematology, medicine, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	587
2	Biostatistics	2	2	220
3	Engineering	1	1	70
4	Health Sciences	1	1	13
5	Blood Transplantation	1	1	27

Bhumika J. Patel

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes Aziz Nazha, Mayur Narkhede, Tomas Radivoyevitch, Leukemia Hematological MalignancyTreated PatientsMedicineMixed-phenotype Acute LeukemiaPrognosis	2016	150
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022 Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali, Journal of the National Comprehensive Cancer Network Hematological MalignancyFamily MedicineNccn Guidelines® InsightsOncologyBone Marrow Failure	2022	121
Genomic determinants of chronic myelomonocytic leukemia Bhumika J. Patel, B Przychodzen, Swapna Thota, Leukemia Hematological MalignancyChromatinMixed-phenotype Acute LeukemiaGeneticsHematology	2017	107
Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network Xiaorong Gu, Rita Tohmé, Benjamin Tomlinson, Leukemia	2020	99
Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL) Srinivasa Reddy Sanikommu, Michael J. Clemente, Peter Chomczynski, Leukemia & lymphoma/Leukemia and lymphoma	2017	95
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms Remco J. Molenaar, Swapna Thota, Yasunobu Nagata, Leukemia Hematological MalignancyBiological ImplicationsSomatic VariantGeneticsHematology	2015	88
Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Carmelo Gurnari, Simona Pagliuca, Pedro Henrique Prata, Journal of Clinical Oncology	2022	72
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes Aziz Nazha, Karam Al-Issa, Betty K. Hamilton, Leukemia Hematological MalignancyOncologyEngineeringMyelodysplastic SyndromesPredictive Power	2017	70
Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia Hassan Awada, Yasunobu Nagata, Abhinav Goyal, Blood Advances	2019	63
Targeted therapy with the mutant <i>IDH2</i> inhibitor enasidenib for high-risk <i>IDH2</i>-mutant myelodysplastic syndrome Courtney D. DiNardo, Sangeetha Venugopal, Curtis A. Lachowiez, Blood Advances	2022	60

Page 1